{
    "clinical_study": {
        "@rank": "77268", 
        "arm_group": [
            {
                "arm_group_label": "NGM282 Dose 1", 
                "arm_group_type": "Experimental", 
                "description": "NGM Dose 1"
            }, 
            {
                "arm_group_label": "NGM282 Dose 2", 
                "arm_group_type": "Experimental", 
                "description": "NGM Dose 2"
            }, 
            {
                "arm_group_label": "NGM282 Dose 3", 
                "arm_group_type": "Experimental", 
                "description": "NGM Dose 3"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety, tolerability, and activity of NGM282\n      in patients with Type 2 Diabetes."
        }, 
        "brief_title": "Phase 2 Study of NGM282 in Patients With Type 2 Diabetes", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or females, between 18 and 70 years of age, inclusive\n\n          -  BMI range of 24-40 kg/m2, inclusive\n\n          -  No active coronary artery disease\n\n          -  Resting heart rate in the range of 40-100 bpm\n\n        Exclusion Criteria:\n\n          -  Diagnosis of Type 1 diabetes\n\n          -  History of significant hypersensitivity, intolerance, or allergy to any drug\n             compound, food, or other substance"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01943045", 
            "org_study_id": "13-0102"
        }, 
        "intervention": {
            "arm_group_label": [
                "NGM282 Dose 1", 
                "NGM282 Dose 2", 
                "NGM282 Dose 3"
            ], 
            "intervention_name": "NGM282", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 18, 2014", 
        "link": {
            "url": "http://ngmbio.com/"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brisbane", 
                        "country": "Australia", 
                        "state": "Queensland"
                    }, 
                    "name": "NGM Clinical Study Site 6106"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "state": "Victoria"
                    }, 
                    "name": "NGM Clinical Study Site 6102"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "state": "Victoria"
                    }, 
                    "name": "NGM Clinical Study Site 6103"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "Australia", 
                        "state": "Victoria"
                    }, 
                    "name": "NGM Clinical Study Site 6104"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Perth", 
                        "country": "Australia", 
                        "state": "Western Australia"
                    }, 
                    "name": "NGM Clinical Study Site 6101"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Auckland", 
                        "country": "New Zealand"
                    }, 
                    "name": "NGM Clinical Study Site 6405"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Auckland", 
                        "country": "New Zealand"
                    }, 
                    "name": "NGM Clinical Study Site 6403"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Christchurch", 
                        "country": "New Zealand"
                    }, 
                    "name": "NGM Clinical Study Site 6401"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tauranga", 
                        "country": "New Zealand"
                    }, 
                    "name": "NGM Clinical Study Site 6404"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wellington", 
                        "country": "New Zealand"
                    }, 
                    "name": "NGM Clinical Study Site 6402"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Australia", 
                "New Zealand"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Activity of NGM282 Administered for 28 Days to Patients With Type 2 Diabetes Mellitus", 
        "overall_contact": {
            "email": "melliott@ngmbio.com", 
            "last_name": "Michael Elliott", 
            "phone": "650-243-5571"
        }, 
        "overall_official": {
            "affiliation": "NGM Biopharmaceuticals, Inc", 
            "last_name": "Alex M DePaoli, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "New Zealand: Medsafe"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Fasting Plasma Glucose", 
            "safety_issue": "No", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01943045"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "HbA1c", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "Lipids", 
                "safety_issue": "No", 
                "time_frame": "28 days"
            }
        ], 
        "source": "NGM Biopharmaceuticals, Inc", 
        "sponsors": {
            "collaborator": {
                "agency": "NGM Biopharmaceuticals Australia Pty Ltd", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "NGM Biopharmaceuticals, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}